BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone

BriaCell Therapeutics Corp

BriaCell Therapeutics Corp

BCTX

0.00
  • Cell-based immunotherapy program is designed to harness patients’ own immune systems
  • Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturing
  • Program builds on BriaCell’s experience in metastatic breast cancer and prostate cancer, further expanding its therapeutic vaccine platform
  • Melanoma remains a significant unmet medical need, with approximately 112,000 new cases and 8,510 deaths expected in the US in 2026
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.